Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2
13 mars 2017 07h00 HE
|
Heat Biologics
Encouraging results evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®) Signs of synergistic efficacy with nivolumab enables expansion to...
Heat Biologics to Present at 29th Annual ROTH Conference
09 mars 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., March 09, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Announces Agreement to Acquire Pelican Therapeutics
08 mars 2017 07h00 HE
|
Heat Biologics
Acquisition brings $15.2 million CPRIT grant to fund 70-patient Phase I trial DURHAM, N.C., March 08, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the...
Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting
02 mars 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium
17 févr. 2017 07h00 HE
|
Heat Biologics
DURHAM, N.C., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), announced that it presented a poster of its immunological data from its 94-patient Phase 2 trial...
Heat Biologics to Present at the Genitourinary Cancers Symposium
14 févr. 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics to Present at NobleCon13
24 janv. 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics to Present at Biotech Showcase 2017 Conference in San Francisco
05 janv. 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer
04 janv. 2017 08h00 HE
|
Heat Biologics
Industry veteran, Dr. Hutchins, to advance Heat’s platform technologies and pursue immunotherapy combinationsFormer CSO Taylor Schreiber, M.D., Ph.D., to chair Heat’s Scientific Advisory Board and...
Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
06 déc. 2016 08h20 HE
|
Heat Biologics
Reports Positive Data on Primary Endpoint with Positive Safety Data Overall Survival Compares Favorably with Single-Agent Nivolumab Management to host a call on Thursday, December 8th, at 8:30 a.m....